Antisense Therapeutics Limited (AU:PER) has released an update.
Percheron Therapeutics Limited is on the brink of completing recruitment for its phase IIb clinical trial of ATL1102 for Duchenne muscular dystrophy, with 37 patients enrolled and more in screening. The company showcased its research with three abstracts presented at a major scientific conference and reported a substantial R&D tax rebate of $1.576 million for the previous fiscal year. These developments signal strong progress in the company’s operations and commitment to addressing rare diseases.
For further insights into AU:PER stock, check out TipRanks’ Stock Analysis page.
